Shaping better health
REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary

2. Cardiovascular System Guidelines

Anticoagulation Guidance

BNSSG DOAC decision aid March 2020

BNSSG Summary of considerations when prescribing a DOAC

BNSSG Anticoagulation questions and answers July 2013

Changing Anticoagulants v53 (undergoing review/update, expected summer 2021)

NBT DOAC counselling checklist (undergoing review/update, expected summer 2021)

NICE KTT16 Anticoagulants including DOACs

DOAC Decision aid July 16

UHB Anticoagulants counselling


 Please see BNSSG COVID-19: Coagulopathy, Thrombosis prevention and DIC

Anticoagulation Patient Information Leaflets (update re links and patient resources expected by July 2021)

Anticoagulation in AF

Apixaban- A Guide for patients with Atrial Fibrillation

Dabigatran- A guide for patients with Atrial Fibrillation

Rivaroxaban- A Guide for patients with Atrial Fibrillation


Antiplatelet Guidance

Antiplatelet Guidelines March 2021 BNSSG


Statin Guidance

BNSSG Management of Blood Lipid Levels (Statin Guidelines) 2020

AAC/NHSE Statin Intolerance Pathway


Heart Failure Guidance

Primary Care Heart Failure Treatment Guideline

Practical Guidance on how to use Heart Failure Medications

Traffic light: How to monitor renal function and potassium rises in stable Heart Failure

Use of Dapagliflozin (SGLT2i) in Patients with Heart Failure with Reduced Ejection Fraction


Raynaud's Phenomenon

Due to significant disruption with the supply of a number of Nifedipine preparations, see local advice document on alternative options for the management of Raynaud's Phenomenon, available here 

Medical Management of Raynauds Phenomenon in view of Nifedipine supply changes (Nov 19).pdf